Chronic hepatitis B (HBsAg positive > 6 months)
HBeAg negative within six months prior to initiation of peginterferon alfa-2a
HBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a
Compensated liver disease
Age > 18 years
Written informed consent

NCT01373684_inc_T1
Condition
Chronic hepatitis B
NCT01373684_inc_T2
Measurement
HBsAg
NCT01373684_inc_T3
Value
positive
NCT01373684_inc_T4
Temporal
> 6 months
NCT01373684_inc_T5
Measurement
HBeAg
NCT01373684_inc_T6
Value
negative
NCT01373684_inc_T7
Temporal
within six months prior to initiation of peginterferon alfa-2a
NCT01373684_inc_T9
Reference_point
initiation of peginterferon alfa-2a
NCT01373684_inc_T10
Drug
peginterferon alfa-2a
NCT01373684_inc_T8
Measurement
HBV DNA
NCT01373684_inc_T11
Value
< 200 IU/ml
NCT01373684_inc_T12
Temporal
within one month prior to initiation of peginterferon alfa-2a
NCT01373684_inc_T13
Reference_point
initiation of peginterferon alfa-2a
NCT01373684_inc_T14
Drug
peginterferon alfa-2a
NCT01373684_inc_T15
Drug
nucleos(t)ide analogue
NCT01373684_inc_T16
Drug
Telbivudine
NCT01373684_inc_T17
Negation
except
NCT01373684_inc_T18
Temporal
during nucleos(t)ide analogue (except Telbivudine) treatment
NCT01373684_inc_T19
Reference_point
nucleos(t)ide analogue (except Telbivudine) treatment
NCT01373684_inc_T20
Condition
liver disease
NCT01373684_inc_T21
Qualifier
Compensated
NCT01373684_inc_T22
Person
Age
NCT01373684_inc_T23
Value
> 18 years